Yonhap Infomax NewsFeb 11
Moderna shares plunged 8% after the FDA refused to review its next-generation flu vaccine, citing clinical trial design issues rather than safety or efficacy concerns.
#YonhapInfomax #Moderna #FDADenial #FluVaccine #ClinicalTrial #SharePriceDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=104937
Moderna’s Flu Vaccine Review Rejected by FDA—Shares Plunge 8% After Hours

Moderna shares plunged 8% after the FDA refused to review its next-generation flu vaccine, citing clinical trial design issues rather than safety or efficacy concerns.

Yonhap Infomax